• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗保健专业人员对美国临床肿瘤学会(ASCO)/欧洲医学肿瘤学会(ESMO)/全球营养不良领导倡议(GLIM)癌症恶病质(CC)诊断和管理指南的了解及遵循情况:乌干达ASSIST-CC基线研究结果

Healthcare professionals' knowledge of and compliance with the ASCO/ESMO/GLIM guidelines for the diagnosis and management of cancer cachexia (CC): the ASSIST-CC baseline findings in Uganda.

作者信息

Atuhe Innocent, Jatho Alfred, Nalwadda Babra, Asasira Judith, Nantayi Martha, Semujju Joseph, Namwira Naome, Namayanja Kulusum, Atwine Ashley, Sekitene Semei Buwambaza, Orem Jackson

机构信息

King Ceasar University, PO Box 88, Kampala, Uganda.

Newton & Einstein Institute of Science and Technology, PO Box 1330, Mbarara, Uganda.

出版信息

Ecancermedicalscience. 2024 Jun 7;18:1712. doi: 10.3332/ecancer.2024.1712. eCollection 2024.

DOI:10.3332/ecancer.2024.1712
PMID:39021540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11254398/
Abstract

BACKGROUND

More than 50% of people with advanced cancer suffer from cancer-related cachexia (CC) - a major contributor to morbidity and mortality. Despite the lack of local guidelines on CC diagnosis and management in Uganda, the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Global Leadership Initiative on Malnutrition (GLIM) developed guidelines on CC screening and management. However, the level of knowledge on CC and compliance with the available guidelines among Ugandan oncology health professionals is unknown. This study aimed to assess the level of among (HCPs) involved in the care of cancer patients.

METHODS

In this phase one, a self-administered structured questionnaire developed using the ASCO/ESMO and GLIM guidelines on diagnosis and management of CC was used to assess the level of awareness, and knowledge of 200 health professionals from three hospital settings on CC, and compliance with the ASCO/ESMO/GLIM guidelines on CC related core communication, barriers to communication, clinician training in communication, discussing goals of care, treatment options and meeting the needs of the underserved populations. The data were entered into Research Electronic Data Capture software analysed using STATA version 18.0 software.

RESULTS

The overall objectively correct knowledge score of CC diagnosis criteria was 67.5% ( = 135), yet there was a much lower level of awareness about ASCO/ESMO/GLIM guidelines on CC at 30% ( = 60) and only 21% ( = 42) of the HCPs have ever assessed Quality of life of CC patients. The compliance with ASCO/ESMO/GLIM guidelines on nutritional interventions for patients with CC varied across the variables markedly, ranging from 25.1% ( = 50) to 81% ( = 162) for the specific ASCO/ESMO/GLIM guidelines' recommendations. Whereas compliance with the guidelines on discussing goals of care, prognosis, treatment options and end-of-life care scored the highest in most variables, most HCPs exhibited low compliance with the discussion about patients' end-of-life preferences early in the course of incurable illness (49.8%, = 99). There were statistically significant differences between the mean scores of only two variables among the three hospitals in compliance with ASCO/ESMO/GLIM guidelines on the provision.

CONCLUSION

This study indicated that the overall objectively correct knowledge of CC diagnosis criteria was inadequate, with a much lower level of awareness about the ASCO/ESMO/GLIM guidelines on CC and a handful of the HCPs have ever assessed the quality of life of CC patients. Quality improvement interventions on CC diagnosis and management should prioritize improving the level of knowledge on CC, diagnostic criteria and patient-clinician communication, including discussion about patients' end-of-life care using standardised tools such as ASCO/ESMO or GLIM guidelines on CC using a multidisciplinary team approach.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7f/11254398/2dd1afc44d82/can-18-1712fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7f/11254398/2dd1afc44d82/can-18-1712fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b7f/11254398/2dd1afc44d82/can-18-1712fig1.jpg
摘要

背景

超过50%的晚期癌症患者患有癌症相关性恶病质(CC),这是发病和死亡的主要原因。尽管乌干达缺乏关于CC诊断和管理的本地指南,但美国临床肿瘤学会(ASCO)、欧洲医学肿瘤学会(ESMO)和全球营养不良领导倡议组织(GLIM)制定了CC筛查和管理指南。然而,乌干达肿瘤健康专业人员对CC的了解程度以及对现有指南的遵循情况尚不清楚。本研究旨在评估参与癌症患者护理的医疗保健专业人员(HCPs)的相关水平。

方法

在这个第一阶段,使用根据ASCO/ESMO和GLIM关于CC诊断和管理的指南开发的自填式结构化问卷,来评估来自三个医院环境的200名健康专业人员对CC的认识水平、知识以及对ASCO/ESMO/GLIM关于CC相关核心沟通、沟通障碍、沟通方面的临床医生培训、讨论护理目标、治疗选择和满足服务不足人群需求的指南的遵循情况。数据录入研究电子数据采集软件,使用STATA 18.0软件进行分析。

结果

CC诊断标准的总体客观正确知识得分是67.5%(n = 135),然而对ASCO/ESMO/GLIM关于CC的指南的知晓水平要低得多,为30%(n = 60),只有21%(n = 42)的HCPs曾评估过CC患者的生活质量。HCPs对ASCO/ESMO/GLIM关于CC患者营养干预指南的遵循情况在不同变量间差异显著,特定ASCO/ESMO/GLIM指南建议的遵循率从25.1%(n = 50)到81%(n = 162)不等。虽然在大多数变量中,关于讨论护理目标、预后、治疗选择和临终护理的指南遵循率最高,但大多数HCPs在不可治愈疾病病程早期对患者临终偏好讨论的遵循率较低(49.8%,n = 99)。在提供方面,三家医院中只有两个变量的平均得分在遵循ASCO/ESMO/GLIM指南方面存在统计学显著差异。

结论

本研究表明,对CC诊断标准的总体客观正确知识不足,对ASCO/ESMO/GLIM关于CC的指南的知晓水平低得多,只有少数HCPs曾评估过CC患者的生活质量。关于CC诊断和管理的质量改进干预措施应优先提高对CC、诊断标准以及医患沟通的知识水平,包括使用标准化工具(如ASCO/ESMO或GLIM关于CC的指南)通过多学科团队方法讨论患者的临终护理。

相似文献

1
Healthcare professionals' knowledge of and compliance with the ASCO/ESMO/GLIM guidelines for the diagnosis and management of cancer cachexia (CC): the ASSIST-CC baseline findings in Uganda.医疗保健专业人员对美国临床肿瘤学会(ASCO)/欧洲医学肿瘤学会(ESMO)/全球营养不良领导倡议(GLIM)癌症恶病质(CC)诊断和管理指南的了解及遵循情况:乌干达ASSIST-CC基线研究结果
Ecancermedicalscience. 2024 Jun 7;18:1712. doi: 10.3332/ecancer.2024.1712. eCollection 2024.
2
Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.衡量新药的价值:4 种肿瘤学评估框架的有效性和可靠性。
J Manag Care Spec Pharm. 2017 Jun;23(6-a Suppl):S34-S48. doi: 10.18553/jmcp.2017.23.6-a.s34.
3
Health care professionals' experiences of dealing with cancer cachexia.医护人员应对癌性恶病质的经验。
Int J Clin Oncol. 2023 Apr;28(4):592-602. doi: 10.1007/s10147-023-02300-6. Epub 2023 Feb 23.
4
Efficacy of Global Leadership Initiative on Malnutrition as potential cachexia screening tool for patients with solid cancer.全球营养不良领导力倡议作为实体瘤患者恶液质筛查工具的疗效。
Nutr J. 2022 Dec 7;21(1):73. doi: 10.1186/s12937-022-00829-2.
5
A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study.一项通过模拟研究比较使用风险比点估计或置信区间界限评估时间事件终点附加获益评估方法的研究。
Med Decis Making. 2024 May;44(4):365-379. doi: 10.1177/0272989X241239928. Epub 2024 May 9.
6
Is hand grip strength a necessary supportive index in the phenotypic criteria of the GLIM-based diagnosis of malnutrition in patients with cancer?握力是否为基于 GLIM 的癌症患者营养不良表型标准诊断中必要的支持性指标?
Support Care Cancer. 2021 Jul;29(7):4001-4013. doi: 10.1007/s00520-020-05975-z. Epub 2021 Jan 4.
7
Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.评估美国临床肿瘤学会的价值框架和欧洲医学肿瘤学会的临床获益程度量表衡量的是绝对还是相对临床生存获益:一项随机临床试验分析
JAMA Oncol. 2019 Aug 1;5(8):1188-1194. doi: 10.1001/jamaoncol.2019.0818.
8
Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.根据 ESMO-MCBS 和 ASCO 框架,晚期胰腺和胃肠神经内分泌肿瘤患者的系统治疗临床获益。
Ann Oncol. 2017 Dec 1;28(12):3022-3027. doi: 10.1093/annonc/mdx547.
9
Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.GLIM 定义的营养不良与握力或步速联合预测合并恶液质的胃癌患者术后结局的预后价值。
BMC Cancer. 2024 Feb 23;24(1):253. doi: 10.1186/s12885-024-11880-z.
10
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.美国食品和药物管理局批准的突破性癌症药物的临床获益和成本。
Cancer. 2020 Oct 1;126(19):4390-4399. doi: 10.1002/cncr.33095. Epub 2020 Jul 22.

本文引用的文献

1
The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey.日本医疗保健提供者在癌症恶病质方面开展跨专业护理的障碍:一项全国性调查。
J Cachexia Sarcopenia Muscle. 2024 Feb;15(1):387-400. doi: 10.1002/jcsm.13384. Epub 2023 Nov 28.
2
Health care professionals' experiences of dealing with cancer cachexia.医护人员应对癌性恶病质的经验。
Int J Clin Oncol. 2023 Apr;28(4):592-602. doi: 10.1007/s10147-023-02300-6. Epub 2023 Feb 23.
3
The Latest Treatments for Cancer Cachexia: An Overview.
癌症恶病质的最新治疗方法:概述。
Anticancer Res. 2023 Feb;43(2):511-521. doi: 10.21873/anticanres.16188.
4
Perspectives of Health Care Professionals on Multimodal Interventions for Cancer Cachexia.医疗保健专业人员对癌症恶病质多模式干预的看法。
Palliat Med Rep. 2022 Dec 2;3(1):244-254. doi: 10.1089/pmr.2022.0045. eCollection 2022.
5
Identification and management of cancer cachexia in patients: Assessment of healthcare providers' knowledge and practice gaps.癌症恶病质患者的识别与管理:评估医疗保健提供者的知识和实践差距。
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2683-2696. doi: 10.1002/jcsm.13105. Epub 2022 Oct 11.
6
Scoping to analyze oncology trial participation in Australia.范围界定分析澳大利亚肿瘤学试验参与情况。
Semin Oncol. 2022 Apr;49(2):178-181. doi: 10.1053/j.seminoncol.2022.04.003. Epub 2022 Apr 29.
7
The good physician and the great physician: why a physician should consider the ESMO guidelines on the management of cancer cachexia?优秀医师与卓越医师:医师为何应考虑欧洲肿瘤内科学会(ESMO)关于癌症恶病质管理的指南?
ESMO Open. 2022 Feb;7(1):100383. doi: 10.1016/j.esmoop.2022.100383. Epub 2022 Jan 25.
8
2021 Presidential Address: Equity: Every Patient. Every Day. Everywhere.2021年主席致辞:公平:每位患者。每日。无处不在。
J Clin Oncol. 2021 Aug 10;39(23):2521-2524. doi: 10.1200/JCO.21.01418. Epub 2021 Jun 25.
9
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines.成人癌症恶病质:ESMO 临床实践指南。
ESMO Open. 2021 Jun;6(3):100092. doi: 10.1016/j.esmoop.2021.100092.
10
Are there systematic barriers to participation in cancer treatment trials by Aboriginal and Torres Strait Islander cancer patients in Australia?澳大利亚原住民和托雷斯海峡岛民癌症患者参与癌症治疗试验是否存在系统性障碍?
Aust N Z J Public Health. 2021 Feb;45(1):39-45. doi: 10.1111/1753-6405.13059. Epub 2020 Dec 21.